Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: State of the art

Expert Opinion on Biological Therapy

Volumn 12, Issue 8, 2012, Pages 1017-1030

  Martino, Massimo ^a   Fedele, Roberta ^a   Cornelio, Giuseppe ^a   Moscato, Tiziana ^a   Imbalzano, Lucrezia ^a   Ressa, Giulia ^a   Massara, Elisabetta ^a   Bresolin, Giuseppe ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

autoimmune disease; cutaneous T cell lymphoma; extracorporeal photoimmune therapy; graft versus host disease; immunological diseases; immunomodulation; organ transplants

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CALCINEURIN INHIBITOR; CLOFAZIMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; METHOXSALEN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PENTOSTATIN; PREDNISONE; RETINOL DERIVATIVE; RITUXIMAB; THALIDOMIDE;

ACCURACY; ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; ATOPIC DERMATITIS; BRONCHIOLITIS OBLITERANS; CANCER PATIENT; CANCER SURVIVAL; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CHRONIC GRAFT VERSUS HOST DISEASE; COST BENEFIT ANALYSIS; CUTANEOUS T CELL LYMPHOMA; DENDRITIC CELL; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EPIDERMOLYSIS BULLOSA ACQUISITA; FORCED EXPIRATORY VOLUME; HEMODYNAMICS; HUMAN; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MEDICAL RECORD REVIEW; NEPHROGENIC SYSTEMIC FIBROSIS; OVERALL SURVIVAL; PEMPHIGUS VULGARIS; PUVA; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNE DISEASES; GRAFT VS HOST DISEASE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; PHOTOPHERESIS; TREATMENT OUTCOME;

EID: 84863791181     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.688025     Document Type: Review

References (134)

1. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1997;316:297-303
2. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 2006;42:1014-30
3. Scarisbrick JJ, Taylor P, Holtick U, et al. UK consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 2008;158:659-78
4. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the apheresis applications committee of the American Society for Apheresis. J Clin Apher 2010;25:83-177
5. Moor AC, Schmitt IM, Beijersbergen van Henegouwen GM, et al. Treatment with 8-MOP and UVA enhances MHC class I synthesis in RMA cells: Preliminary results. J Photochem Photobiol B 1995;29:193-8
6. Ullrich SE. Photoinactivation of T-cell function with psoralen and UVA radiation suppresses the induction of experimental murine graft-versus-host disease across major histocompatibility barriers. J Invest Dermatol 1991;96:303-8
7. Suchin KR, Cassin M, Washko R, et al. Extracorporeal photochemotherapy does not suppress T or B cell responses to novel or recall antigens. J Am Acad Dermatol 1999;41:980-6
8. Scarisbrick JJ, Taylor P, Holtick U, et al. UK consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 2008;158:659-78
9. McKenna KE, Whittaker S, Rhodes LE, et al. Evidence-based practice of photopheresis 1987-2001: A report of a workshop of the British Photodermatology Group and the UK Skin Lymphoma Group. Br J Dermatol 2006;154(1):7-20
10. Gottlieb S, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alpha, a 10 year experience at a single institution. J Am Acad Dermatol 1996;35:946-57
11. Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GVHD: Second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011;17:1-17
12. Yoo EK, Rook AH, Elenitsas R, et al. Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: Relevance to mechanism of therapeutic action. J Invest Dermatol 1996;108:235-42
13. Heshmati F, Andreu G. Extracorporeal photochemotherapy: A historical perspective. Transfus Apheresis Sci 2003;28:25-34
14. Rook AH, Suchin KR, Kao DMF, et al. Photopheresis: Clinical applications and mechanism of action. J Invest Dermatol Symp Proc 1999;4:85-90
15. Alcindor T, Gorgun G, Miller KB, et al. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 2001;98:1622-5
16. Tambur AR, Ortegel JW, Morales A, et al. Extracorporeal photopheresis induces lymphocyte but not monocyte apoptosis. Transplant Proc 2000;32:747-8
17. Salskov-Iversen M, Berger CL. Rapid construction of dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loading. J Immune Based Ther Vaccines 2005;3:4
18. Spisek R, Gasova Z, Bartunkova J. Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft-versus-host disease. Transfusion 2006;46:55-65
19. Berger CL, Xu AL, Hanlon D, et al. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001;91:438-47
20. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004;350:1978-88
21. Yoo EK, Rook AH, Elenitsas R, et al. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma, relevance to mechanism of therapeutic action. J Invest Dermatol 1996;107:235-42
22. Bladon J, Taylor PC. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br J Haematol 1999;107:707-11
23. Zouboulis CC, Schmuth M, Doepfmer S, et al. Extracorporeal photopheresis of cutaneous T-cell lymphoma is associated with reduction of peripheral CD4 T lymphocytes. Dermatology 1998;196:305-8
24. Di Renzo M, Rubegni P, De Aloe G, et al. Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma. Immunology 1997;92:99-103
25. Vowels BR, Cassin M, Boufal MH, et al. Extracorporeal photochemotherapy induces the production of tumor necrosis factor-alpha by monocytes, implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis. J Invest Dermatol 1992;98:686-92
26. Edelson RL. Photopheresis, a clinically relevant immunobiologic response modifier. Ann NY Acad Sci 1991;636:154-64
27. Coghill JM, Sarantopoulos S, Moran TP, et al. Effector CD4+ T cells, the cytokines they generate, and GVHD: Something old and something new. Blood 2011;177:3268-76
28. Paczesny S, Hanauer D, Sun Y, Reddy P. New perspectives on the biology of GVHD. Bone Marrow Transplant 2010;45:1-11
29. Dustin ML. Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol 2001;21:258-63
30. Anderson BE, McNiff JM, Jain D, et al. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: Requirements depend on target organ. Blood 2005;105:2227-34
31. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12(Suppl 2):7-12
32. Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008;112:1515-21
33. Gorgun G, Miller KB, Foss FM. Immunologic mechanism of extracorporeal photochemotherapy in chronic graft versus-host disease. Blood 2002;100:941-7
34. Foss FM, Gorgun G, Miller KB. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant 2002;29(9):719-25
35. Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008;112:1515-21
36. Aubin F, Mousson C. Ultraviolet light-induced regulatory (suppressor) T cells: An approach for promoting induction of operational allograft tolerance? Transplantation 2004;77(1 Suppl):29-31
37. Di Renzo M, Sbano P, De Aloe G. Extracorporeal photopheresis affects co-stimulatory molecule expression and interleukin-10 production by dendritic cells in graft-versus-host disease patients. Clin Exp Immunol 2008;151:407-13
38. Bladon J, Taylor P. Extracorporeal photopheresis normalizes some lymphocyte subsets (including T regulatory cells) in chronic graft-versushost-disease. Ther Apher Dial 2008;12:311-18
39. Biagi E, Di Biaso I, Leoni V, et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+ Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 2007;84:31-9
40. Heshmati F. Mechanisms of action of extracorporeal photochemotherapy. Transfus Apher Sci 2003;29:61-70
41. Geskin L. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma. Skin Therapy Lett 2007;12(5):1-4
42. Rook AH, Wolfe JT. Role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection. J Clin Apher 1994;9:28-30
43. Stevens SR, Baron ED, Masten S, Cooper KD. Circulating CD4+CD7-lymphocyte burden and rapidity of response: Predictors of outcome in the treatment of Sezary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis. Arch Dermatol 2002;138:1347-50
44. Lim HW, Edelson RL. Photopheresis for the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1117-26
45. Fraser-Andrew E, Seed P, Whittaker S, Russel-Jones R. Extracorporeal photopheresis in Sezary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch Dermatol 1998;134:1001-5
46. Russel-Jones R. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol 2000;142:16-21
47. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T cell lymphoma. J Am Acad 1996;35:573-9
48. Rook A, Prystowsky MB, Cassin M, et al. Combined therapy for Sezary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Arch Dermatol 1991;127:1535-40
49. Jumbou O, N'Guyen JM, Tessier MH, et al. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol 1999;140:427-31
50. Fimiani M, Rubegni P, De Aloe G, Andreassi L. Role of extracorporeal photochemotherapy alone and in combination with interferon alfa in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1999;41:502-3
51. Fritz TM, Kleinhans M, Nestle FO, et al. Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin- 2 in a patient with the Sezary syndrome. Br J Dermatol 1999;140:1144-7
52. Rook AH, Gottlieb SL, Wolfe JT, et al. Pathogenesis of cutaneous T-cell lymphoma, implication for the use of recombinant cytokines and photopheresis. Clin Exp Immunol 1997;107:16-20
53. Rook AH, Wood GS, Yoo EK, et al. Interleukin 12 induces lesion regression and cytotoxic T cell responses in cutaneous T cell lymphomas. Blood 1999;94:902-8
54. Bouwhuis SA, Markovic SN, McEvoy MT, Pittelkow MR. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sezary syndrome. Mayo Clin Proc 2002;77:197-200
55. Wilson LD, Licata AL, Braverman IM, et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys 1995;32:987-95
56. Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythodermic (T4) mycosis fungoides. J Am Acad Dermatol 2000;43:54-60
57. Siakantaris MP, Tsirigotis P, Stavroyianni N, et al. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience. Transfus Apher Sci 2012;46(2):189-93
58. Child FJ, Mitchell TJ, Whittaker SJ, et al. A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clin Exp Dermatol 2004;29(3):231-6
59. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1994;15:825-8
60. Rowlings P, Przepiorka D, Klein J, et al. IBMTR severity index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade. Br J Haematol 1997;97:855-64
61. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17
62. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-62
63. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2005;11:945-56
64. Vigorito AC, Campregher PV, Storer BE, et al. National Institutes of Health. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009;114:702-8
65. Greinix HT, Loddenkemper C, Pavletic SZ, et al. Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant 2011;17:167-75
66. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: A multicenter randomized trial from the Italian group for bone marrow transplantation. Blood 1998;92:2288-93
67. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: Significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006;107:4177-82
68. Martin PJ, Shoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment. Blood 1991;62:626-31
69. Bacigalupo A, Palandri F. Management of acute graft-versus host disease (GVHD). Hematol J 2004;5:189-96
70. Rossetti F, Dall'Amico R, Provetti G, et al. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Bone Marrow Transplant 1996;18(Suppl 2):175-81
71. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003;122:118-27
72. Kanold J, Paillard C, Halle P, et al. Extracorporeal photochemotherapy for graft versus host disease in pediatric patients. Transfus Apher Sci 2003;28:71-80
73. Greinix HT, Volc-Platzer B, Rabitsh W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998;92:3098-104
74. Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006;91:405-8
75. Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: A pilot study. Blood 2000;96:2426-31
76. Perfetti P, Carlier P, Strada P, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008;42:609-17
77. Calore E, Calo A, Tridello G, et al. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant 2008;42:421-5
78. Merlin E, Paillard C, Rochette E, et al. Extracorporeal photochemotherapy as second- or first-line therapy of acute GVHD? Bone Marrow Transplant 2010;45:963-5
79. Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): First-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010;16:1611-12
80. Child FJ, Ratnavel R, Watkins P, et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 1999;23:881-7
81. Bisaccia E, Palangio M, Gonzalez J, et al. Treating refractory chronic graft-versus-host disease with extracorporeal photochemotherapy. Bone Marrow Transplant 2003;31:291-4
82. Rubegni P, Cuccia A, Sbano P, et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. Br J Haematol 2005;130:271-5
83. Apisarnthanarax N, Donato M, Korbling M, et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: Feasibility and results. Bone Marrow Transplant 2003;31:459-65
84. Dall'Amico R, Rossetti F, Zulian F, et al. Photopheresis in pediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol 1997;97:848-54
85. Ilhan O, Arat M, Arslan O, et al. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. Transfus Apher Sci 2004;30:185-7
86. Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006;107:3074-80
87. Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid resistant extensive chronic graft-versus-host disease: Analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005;35:1187-93
88. Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002;100:941-7
89. Greinix HT, Socie G, Bacigalupo A, et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant 2006;38:265-73
90. Kanold J, Messina C, Halle P, et al. Update on extracorporeal photochemotherapy for graft-versus-host disease treatment. Bone Marrow Transplant 2005;35(Suppl 1):69-71
91. Seaton ED, Szydlo RM, Kanfer E, et al. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 2003;102:1217-23
92. Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008;112:1515-21
93. Perseghin P, Galimberti S, Balduzzi A, et al. Extracorporeal photochemotherapy for the treatment of chronic graft versus-host disease: Trend for a possible cell dose-related effect? Ther Apher Dial 2007;11:85-93
94. Salvaneschi L, Perotti C, Zecca M, et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion 2001;41:1299-305
95. Perotti C, Del Fante C, Tinelli C, et al. Extracorporeal photochemotherapy for graft-versus-host disease: A longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion 2010;50:1359-69
96. Owsianowski M, Gollnick H, Siegert W, et al. Successful treatment of chronic graft-versus-host disease with extracorporeal photochemotherapy. Bone Marrow Transplant 1994;14:845-8
97. Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008;112:2667-74
98. Greinix HT, van Besien K, Elmaagacli AH, et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis-results of a crossover randomized study. Biol Blood Marrow Transplant 2001;17:1775-82
99. Dignan FL, Greenblatt D, Cox M, et al. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. Bone Marrow Transplant 2011;doi 10.1038/bmt.2011.186
100. Tsirigotis P, Kaloyannidis P, Papalexandri A, et al. Extracorporeal photopheresis in the treatment of chronic graft-versus-host disease. The Hellenic experience: A study by the Hellenic association of hematology. Transfus Apher Sci 2012;46(2):173-80
101. Tsirigotis P, Kapsimalli V, Baltadakis I, et al. Extracorporeal photopheresis in refractory chronic graft-versus-host disease: The influence on peripheral blood T cell subpopulations. A study by the Hellenic Association of Hematology. Transfus Apher Sci 2012;46(2):181-8
102. Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002;6:296-304
103. Kanold J, Merlin E, Halle P, et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: Clinical practice guidelines based on field experience and review of the literature. Transfusion 2007;47:2276-89
104. Perseghin P, Dassi M, Balduzzi A, et al. Mononuclear cell collection in patients undergoing extra-corporeal photochemotherapy for acute and chronic graft-vs.-host-disease (GvHD): Comparison between COBE Spectra version 4.7 and 6.0 (AutoPBSC). J Clin Apher 2002;17:65-71
105. Perutelli P, Rivabella L, Lanino E, et al. ATP downregulation in mononuclear cells from children with graft-versus-host disease following extracorporeal photochemotherapy. Haematologica 2002;87:335-6
106. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998;339:1744-51
107. O'Hagan AR, Stillwell PC, Arroliga A, et al. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest 1999;115:1459-62
108. Benden C, Speich R, Hofbauer GF, et al. Extracorporeal photopheresis after lung transplantation: A 10-year single-center experience. Transplantation 2008;86:1625-7
109. Morrell MR, Despotis GJ, Lublin DM, et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010;29:424-31
110. Rook AH, Freundlich B, Nahass GT, et al. Treatment of autoimmune disease with extracorporeal photochemotherapy progressive systemic sclerosis. Yale J Biol Med 1989;62:639-45
111. Rook AH, Freundlich B, Jegasothy BV. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Result of a multicenter trial. Arch Dermatol 1992;128:337-46
112. Di Spaltro FX, Cotrill C, Cahill C, et al. Extracorporeal photochemotherapy in progressive systemic sclerosis. Int J Dermatol 1993;32:417-21
113. Krasagakis K, Dippel E, Ramaker J, et al. Management of severe scleroderma with long term extra-corporeal photopheresis. Dermatology 1998;196:309-15
114. Knobler R, French LE, Kim Y, et al. A randomized, double-blind, placebo controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol 2006;54:793-9
115. Enonoto DNH, Mekkes JR, Bossuyt PMM, et al. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 1999;41:915-22
116. Cribier B, Faradji T, Le Coz C, et al. Extracorporeal photochemotherapy in systemic sclerosis and severe morphea. Dermatology 1995;191:25-31
117. Zic JA, Miller JL, Stricklin GP, King LE Jr. The North American experience with photopheresis. Ther Apher 1999;3:50-62
118. Rook AH, Jegasothy BV, Heal P, et al. Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris. Ann Intern Med 1990;112:303-5
119. Liang G, Nahass G, Kerdel FA. Pemphigus vulgaris treated with photopheresis. J Am Acad Dermatol 1992;26:779-80
120. Gollnick HPM, Owsianowski M, Taube KM. Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis. J Am Acad Dermatol 1993;28:122-4
121. Wollina U, Lange D, Looks A. Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune bullous diseases. Dermatology 1999;198:140-4
122. Prinz B, Nachbar F, Plewig G. Treatment of severe atopic dermatitis with extracorporeal photopheresis. Arch Dermatol Res 1994;287:48-52
123. Prinz B, Michelsen S, Pfeiffer C, Plewig G. Long-term application of extracorporeal photochemotherapy in severe atopic dermatitis. J Am Acad Dermatol 1999;40:577-82
124. Radenhausen M, von Kobylezki G, Hoxtermann S, et al. Activation markers in severe atopic dermatitis following extracorporeal photochemotherapy. Acta Dermatol Venereol 2003;83:49-79
125. Ritcher HI, Billmann-Eberwein C, Grewe M, et al. Successful monotherapy of severe and intractable atopic dermatitis by photopheresis. J Am Acad Dermatol 1998;38:585-8
126. Mohla G, Horvath N, Stevens S. Quality of life improvement in a patient with severe atopic dermatitis treated with photopheresis. J Am Acad Dermatol 1999;40:780-2
127. Knobler RM, Graninger W, Lindmaier A, et al. Extracorpreal photochemotherapy for the treatment of SLE: A pilot study. Arthritis Rheum 1992;35:319-24
128. Malawsta S, Trock D, Edelson R. Treatment of rheumatoid arthritis by extracorporeal photochemotherapy: A pilot study. Arthritis Rheum 1991;34:646-54
129. Miller J, Stricklin G, Fine J, et al. Remission of severe epidermolysis bullosa acquisita by extracorporeal photochemotherapy. Br J Dermatol 1995;133:467-71
130. Gordon K, Chan L, Woodley D. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol 1997;136:415-20
131. Ludvigsson J, Samuelsson U, Ernerudh J, et al. Photopheresis at onset of type 1 diabetes, a randomised, double blind, placebo controlled trial. Arch Dis Child 2001;85:149-54
132. O'Brien CB, Henzel BS, Moonka DK, et al. Extracorporeal photopheresis alone and with interferon-alpha 2a in chronic hepatitis C patients who failed previous interferon therapy. Dig Dis Sci 1999;44:1020-6
133. Reinisch W, Nahavandi H, Santella R, et al. Extracorporeal photochemotherapy in patients with steroid dependent Crohn's disease, a prospective pilot study. Aliment Pharmacol Ther 2001;15:1313-22
134. Abreu MT, von Tirpitz C, Hardi R, et al. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study. Inflamm Bowel Dis 2009;15:829-36